Trial Profile

A study to assess the effectiveness and safety of adjunctive cenobamate treatment during routine clinical practice in patients with uncontrolled focal seizures

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Dec 2022 Results(n=25) assessing Long-term Effectiveness and Safety of Adjunctive Cenobamate for Patients with Uncontrolled Focal Seizures Living in a Group Home or with a Developmental Disability following 12 months of cenobamate treatment presented at the 76th Annual Meeting of the American Epilepsy Society
26 Apr 2022 Results assessing effectiveness and safety of cenobamate during routine clinical practice in patients with uncontrolled focal seizures living in a group home or with a developmental disability presented at the 74th Annual Meeting of the American Academy of Neurology 2022
18 Feb 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com